Fatal Outcome of COVID-19 Relapse in a Fully Vaccinated Patient with Non-Hodgkin Lymphoma Receiving Maintenance Therapy with the Anti-CD20 Monoclonal Antibody Obinutuzumab: A Case Report
Abstract
:1. Background
2. Methods
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- European Centre for Disease Prevention and Control. COVID-19 Situation Update Worldwide, as of Week 17, Updated 5 May 2022. Available online: https://www.ecdc.europa.eu/en/covid-19/situation-updates (accessed on 5 May 2022).
- Liang, W.; Guan, W.; Chen, R.; Wang, W.; Li, J.; Xu, K.; Li, C.; Ai, Q.; Lu, W.; Liang, H.; et al. Cancer Patients in SARS-CoV-2 Infection: A Nationwide Analysis in China. Lancet Oncol. 2020, 21, 335–337. [Google Scholar] [CrossRef]
- Du, Y.; Tu, L.; Zhu, P.; Mu, M.; Wang, R.; Yang, P.; Wang, X.; Hu, C.; Ping, R.; Hu, P.; et al. Clinical Features of 85 Fatal Cases of COVID-19 From Wuhan. A Retrospective Observational Study. Am. J. Respir. Crit. Care Med. 2020, 201, 1372–1379. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Goldman, J.D.; Gonzalez, M.A.; Rüthrich, M.M.; Sharon, E.; von Lilienfeld-Toal, M. COVID-19 and Cancer: Special Considerations for Patients Receiving Immunotherapy and Immunosuppressive Cancer Therapies. Am. Soc. Clin. Oncol. Educ. Book 2022, 42, 1–13. [Google Scholar] [CrossRef] [PubMed]
- Monari, C.; Sagnelli, C.; Maggi, P.; Sangiovanni, V.; Numis, F.G.; Gentile, I.; Masullo, A.; Rescigno, C.; Calabria, G.; Megna, A.S.; et al. More Severe COVID-19 in Patients with Active Cancer: Results of a Multicenter Cohort Study. Front. Oncol. 2021, 11, 662746. [Google Scholar] [CrossRef] [PubMed]
- John, B.V.; Deng, Y.; Scheinberg, A.; Mahmud, N.; Taddei, T.H.; Kaplan, D.; Labrada, M.; Baracco, G.; Dahman, B. Association of BNT162b2 mRNA and mRNA-1273 Vaccines with COVID-19 Infection and Hospitalization Among Patients with Cirrhosis. JAMA Intern. Med. 2021, 181, 1306–1314. [Google Scholar] [CrossRef] [PubMed]
- Barda, N.; Dagan, N.; Cohen, C.; A Hernán, M.; Lipsitch, M.; Kohane, I.S.; Reis, B.Y.; Balicer, R.D. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: An observational study. Lancet 2021, 398, 2093–2100. [Google Scholar] [CrossRef]
- Marchesi, F.; Pimpinelli, F.; Giannarelli, D.; Ronchetti, L.; Papa, E.; Falcucci, P.; Pontone, M.; Di Domenico, E.G.; di Martino, S.; Laquintana, V.; et al. Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin’s lymphomas. Leukemia 2022, 36, 588–590. [Google Scholar] [CrossRef] [PubMed]
- Ghione, P.; Gu, J.J.; Attwood, K.; Torka, P.; Goel, S.; Sundaram, S.; Mavis, C.; Johnson, M.; Thomas, R.; McWhite, K.M.; et al. Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell–directed therapies. Blood 2021, 138, 811–814. [Google Scholar] [CrossRef] [PubMed]
- Várnai, C.; Palles, C.; Arnold, R.; Curley, H.M.; Purshouse, K.; Cheng, V.W.T.; Booth, S.; Campton, N.A.; Collins, G.P.; Hughes, D.J.; et al. Mortality Among Adults with Cancer Undergoing Chemotherapy or Immunotherapy and Infected With COVID-19. JAMA Netw. Open 2022, 5, e220130. [Google Scholar] [CrossRef] [PubMed]
- Deveci, B.; Saba, R. Prolonged viral positivity induced recurrent coronavirus disease 2019 (COVID-19) pneumonia in patients receiving anti-CD20 monoclonal antibody treatment: Case reports. Medicine 2021, 100, e28470. [Google Scholar] [CrossRef] [PubMed]
- Lee, C.Y.; Shah, M.K.; Hoyos, D.; Solovyov, A.; Douglas, M.; Taur, Y.; Maslak, P.; Babady, N.E.; Greenbaum, B.; Kamboj, M.; et al. Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies. Cancer Discov. 2022, 12, 62–73. [Google Scholar] [CrossRef] [PubMed]
- Marcacci, G.; Fiorentino, G.; Volzone, F.; Falcone, U.; Parrella, R.; Donnarumma, D.; D’Ovidio, S.; Annunziata, A.; Micallo, G.; Portella, G.; et al. Atypical COVID-19 dynamics in a patient with mantle cell lymphoma exposed to rituximab. Infect. Agents Cancer 2021, 16, 38. [Google Scholar] [CrossRef] [PubMed]
- Naranbhai, V.; Pernat, C.A.; Gavralidis, A.; Denis, K.J.S.; Lam, E.C.; Spring, L.M.; Isakoff, S.J.; Farmer, J.R.; Zubiri, L.; Hobbs, G.S.; et al. Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients with Cancer: The CANVAX Cohort Study. J. Clin. Oncol. 2022, 40, 12–23. [Google Scholar] [CrossRef] [PubMed]
- Fendler, A.; Shepherd, S.T.C.; Au, L.; Wilkinson, K.A.; Wu, M.; Byrne, F.; Cerrone, M.; Schmitt, A.M.; Joharatnam-Hogan, N.; Shum, B.; et al. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study. Nat. Cancer 2021, 2, 1305–1320. [Google Scholar] [CrossRef] [PubMed]
- Zeng, C.; Evans, J.P.; Chakravarthy, K.; Qu, P.; Reisinger, S.; Song, N.-J.; Rubinstein, M.P.; Shields, P.G.; Li, Z.; Liu, S.-L. COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer. Cancer Cell 2022, 40, 117–119. [Google Scholar] [CrossRef] [PubMed]
- Weinbergerová, B.; Demel, I.; Víšek, B.; Válka, J.; Čerňan, M.; Jindra, P.; Novák, J.; Stejskal, L.; Kovácsová, F.; Kabut, T.; et al. Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients—A Czech multicenter experience. Hematol. Oncol. 2022, 40, 280–286. [Google Scholar] [CrossRef] [PubMed]
- Thompson, M.A.; Henderson, J.P.; Shah, P.K.; Rubinstein, S.M.; Joyner, M.J.; Choueiri, T.K.; Flora, D.B.; Griffiths, E.A.; Gulati, A.P.; Hwang, C.; et al. Association of Convalescent Plasma Therapy with Survival in Patients with Hematologic Cancers and COVID-19. JAMA Oncol. 2021, 7, 1167–1175. [Google Scholar] [CrossRef] [PubMed]
- Oliva, A.; Cancelli, F.; Brogi, A.; Curtolo, A.; Savelloni, G.; Siccardi, G.; Marcelli, G.; Mazzuti, L.; Ricci, P.; Turriziani, O.; et al. Convalescent plasma for haematological patients with SARS-CoV-2 pneumonia and severe depletion of B-cell lymphocytes following anti-CD20 therapy: A single-centre experience and review of the literature. New Microbiol. 2022, 45, 62–72. [Google Scholar] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Calò, F.; Onorato, L.; Pisaturo, M.; Pinto, A.; Alessio, L.; Monari, C.; Minichini, C.; Arcamone, M.; Di Fraia, A.; Atripaldi, L.; et al. Fatal Outcome of COVID-19 Relapse in a Fully Vaccinated Patient with Non-Hodgkin Lymphoma Receiving Maintenance Therapy with the Anti-CD20 Monoclonal Antibody Obinutuzumab: A Case Report. Vaccines 2022, 10, 1021. https://doi.org/10.3390/vaccines10071021
Calò F, Onorato L, Pisaturo M, Pinto A, Alessio L, Monari C, Minichini C, Arcamone M, Di Fraia A, Atripaldi L, et al. Fatal Outcome of COVID-19 Relapse in a Fully Vaccinated Patient with Non-Hodgkin Lymphoma Receiving Maintenance Therapy with the Anti-CD20 Monoclonal Antibody Obinutuzumab: A Case Report. Vaccines. 2022; 10(7):1021. https://doi.org/10.3390/vaccines10071021
Chicago/Turabian StyleCalò, Federica, Lorenzo Onorato, Mariantonietta Pisaturo, Antonio Pinto, Loredana Alessio, Caterina Monari, Carmine Minichini, Manuela Arcamone, Alessandra Di Fraia, Luigi Atripaldi, and et al. 2022. "Fatal Outcome of COVID-19 Relapse in a Fully Vaccinated Patient with Non-Hodgkin Lymphoma Receiving Maintenance Therapy with the Anti-CD20 Monoclonal Antibody Obinutuzumab: A Case Report" Vaccines 10, no. 7: 1021. https://doi.org/10.3390/vaccines10071021